中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 合肥物质科学研究院
  3. 中国科学院合肥物质科学研究院
High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma

文献类型：期刊论文

作者Chen, Xi5,6; Kong, Haiying4; Luo, Linxiang3; Han, Shuiyun5,6; Lei, Tao5,6; Yu, Haifeng5,6; Guo, Na2,5; Li, Cong5,6; Peng, Shuailing5,6; Dong, Xiaowu1
刊名BMC CANCER
出版日期2022-01-03
卷号22
关键词Hodgkin lymphoma PD-1 inhibitor PD-L1 inhibitor PD-L2 Molecular phenotype Tumor microenvironment
DOI10.1186/s12885-021-09028-4
通讯作者Yang, Haiyan(haiyanyang1125@163.com) ; Wu, Meijuan(wumj@zjcc.org.cn)
英文摘要Purpose: We sought to understand the clinical course and molecular phenotype of patients who showed disease progression after programmed cell death ligand 1 (PD-L1) inhibitor treatment but subsequently responded to PD-1 inhibitor treatment. We also explored the response to PD-1-axis targeted therapy of classical Hodgkin lymphoma (cHL) according to genetically driven PD-L1 and programmed cell death ligand 2 (PD-L2) expression. Methods: Five patients in a phase II clinical trial of CS1001 (PD-L1 inhibitor) for relapsed or refractory (R/R) cHL were retrospectively reviewed. Formalin-fixed, paraffin-embedded whole tissues from the five patients were evaluated for 9p24.1 genetic alterations based on FISH and the expression of PD-L1, PD-L2, PD-1, major histocompatibility complex (MHC) class I-II, and the tumor microenvironment factorsCD163 and FOXP3 in the microenvironmental niche, as revealed by multiplex immunofluorescence. Results: All five patients showed primary refractory disease during first-line treatment. Four patients received PD-1 inhibitor after dropping out of the clinical trial, and all demonstrated at least a partial response. The progression-free survival ranged from 7 to 28 months (median = 18 months), and 9p24.1 amplification was observed in all five patients at the PD-L1/PD-L2 locus. PD-L1 and PD-L2 were colocalized on Hodgkin Reed-Sternberg (HRS) cells in four of the five (80%) patients. There was differential expression of PD-L1 and PD-L2 in cells in the tumor microenvironment in cHL, especially in HRS cells, background cells and tumor-associated macrophages. Conclusions: PD-L1 monotherapy may not be sufficient to block the PD-1 pathway; PD-L2 was expressed in HRS and background cells in cHL. The immunologic function of the PD-L2 pathway in anti-tumor activity may be underestimated in R/R cHL. Further study is needed to elucidate the anti-tumor mechanism of PD-1 inhibitor and PD-L1 inhibitor treatment.
WOS关键词TUMOR-ASSOCIATED MACROPHAGES ; ANALYSIS REVEALS ; FOLLOW-UP ; EXPRESSION ; CELLS ; NIVOLUMAB ; BLOCKADE ; CD163 ; CD68
资助项目Science and Technology Program of Zhejiang Provincial Traditional Chinese Medicine[2021ZB038]
WOS研究方向Oncology
语种英语
WOS记录号WOS:000738001600023
出版者BMC
资助机构Science and Technology Program of Zhejiang Provincial Traditional Chinese Medicine
源URL[http://ir.hfcas.ac.cn:8080/handle/334002/127247]  
专题中国科学院合肥物质科学研究院
通讯作者Yang, Haiyan; Wu, Meijuan
作者单位1.Zhejiang Univ, Coll Pharmaceut Sci, Hangzhou Inst Innovat Med, Hangzhou, Peoples R China
2.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Pathol, 1 Banshan East Rd, Hangzhou, Peoples R China
3.Zhejiang Quhua Hosp, Dept Hematol, Quhua, Peoples R China
4.Hangzhou Hanggang Hosp, Dept Pharm, Zhejiang Med & Hlth Grp, Hangzhou Hosp, Hangzhou, Peoples R China
5.Chinese Acad Sci, Inst Canc & Basic Med IBMC, Hangzhou, Peoples R China
6.Univ Chinese Acad Sci, Dept Lymphoma, Canc Hosp, Zhejiang Canc Hosp, Hangzhou, Peoples R China
推荐引用方式
GB/T 7714		 Chen, Xi,Kong, Haiying,Luo, Linxiang,et al. High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma[J]. BMC CANCER,2022,22.
APA Chen, Xi.,Kong, Haiying.,Luo, Linxiang.,Han, Shuiyun.,Lei, Tao.,...&Wu, Meijuan.(2022).High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma.BMC CANCER,22.
MLA Chen, Xi,et al."High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma".BMC CANCER 22(2022).

入库方式： OAI收割

来源：合肥物质科学研究院

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。